You are here

Consultation: Proposed minor changes to Required Advisory Statements for Medicine Labels (RASML): Chlorhexidine, hydrocortisone, ibuprofen

6 August 2021

This consultation closes on 17 September 2021

The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on proposed minor changes to advisory statement requirements for labels of over the counter (OTC) medicines containing chlorhexidine, hydrocortisone or ibuprofen, for inclusion in the Required Advisory Statements for Medicine Labels (RASML). The proposed changes involve minor changes to existing RASML entries to correct or clarify intended requirements and in most cases should not require changes to existing product labels.

For more information and to participate in the consultation, please visit consultation hub.

Timetable

The consultation opens on Friday 6 August 2021. Interested parties should respond by close of business Friday 17 September 2021.

Enquiries

Any questions relating to submissions should be emailed to rasml@health.gov.au.